UBS Group AG Has $8.21 Million Stock Holdings in Oruka Therapeutics, Inc. $ORKA

UBS Group AG raised its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 213.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 271,013 shares of the company’s stock after buying an additional 184,453 shares during the quarter. UBS Group AG owned 0.56% of Oruka Therapeutics worth $8,214,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc acquired a new position in Oruka Therapeutics in the 2nd quarter valued at approximately $28,000. BNP Paribas Financial Markets increased its stake in shares of Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth $39,000. Russell Investments Group Ltd. acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth $43,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Oruka Therapeutics by 62.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after purchasing an additional 904 shares during the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $61.93 on Monday. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of -31.92 and a beta of -0.20. The company’s fifty day moving average is $55.17 and its two-hundred day moving average is $39.42. Oruka Therapeutics, Inc. has a 52-week low of $9.40 and a 52-week high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, sell-side analysts expect that Oruka Therapeutics, Inc. will post -2.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ORKA shares. Wall Street Zen upgraded shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. HC Wainwright increased their price target on shares of Oruka Therapeutics from $75.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. UBS Group increased their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Stifel Nicolaus increased their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $120.80.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $61.85, for a total value of $432,950.00. Following the sale, the insider directly owned 33,377 shares in the company, valued at $2,064,367.45. This trade represents a 17.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the sale, the chief executive officer owned 927,309 shares in the company, valued at $38,297,861.70. This represents a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,765 shares of company stock worth $1,522,695 over the last 90 days. Company insiders own 23.49% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.